KROYNAS Pvt. Ltd. is the First and Only company in India providing services catering to Dental Genetics as well as clinical medicine using saliva diagnostics and genomic technologies.
We are presently working to develop the world's first non-invasive kit STOP (TM) for detecting oral cancer just at its inception even in asymptomatic individuals as well as that can predict at which stage it has reached
Through our academic endeavors (Indian Academy for Clinical and Dental Genetics), we are trying our best to bridge the gap of knowledge that presently prevails between the basic sciences and dental and clinical sciences. Our academic drive is to establish oral healthcare research as a parallel career alongwith clinical dentistry. We promote the benefits of embracing interdisciplinary scientific knowledge. and looking "Beyond the Textbook".
Saliva Diagnostics Devices
We are the exclusive partner representing Oasis Diagnostics® Corporation, USA in India. The unique proprietary range of saliva collection products which includes the *VerOFy® oral fluid rapid test platform, the *Versi•SAL® split sample saliva / oral fluid collection device, the DNA•SAL™ Salivary DNA collection device, Super•SAL™, a device for universal saliva collection and RNAPro•SAL™, a novel device for RNA and or protein collection for genomic applications or proteomics and LIAM™ [Light Image Analysis Module], a reading device for lateral flow test assessment and quantification.
Point of Care Testing
Point of care testing is extremely effective when health care decisions must be made and appropriate actions must be taken in real time. Point-of-care testing provides immediate results when the patient is still at the clinic or other remote testing site. The resulting outcome is usually a more rapid diagnosis of disease leading to earlier enrollment into treatment regimens. Point-of-care testing is usually cost effective and can be performed by individuals with minimal training.
Oasis's VerOFy® point-of-care testing device is an enabling technology that may be used as the platform for the development of a series of qualitative and quantitative rapid saliva based diagnostic tests using lateral flow immunochromatography, latex agglutination, magnetic beads and others. Currently, we are interested in the areas of:
Molecular diagnostics is the driving force behind unraveling our biological makeup at the genetic level. It analyzes genetic content for disease information and can examine specific DNA regions to identify genetic mutations/genetic materials that may result from bacterium, viruses or cancer. New technologies also look at RNA through micro RNAs and mRNAs. A person who is predisposed to a particular disease can make certain lifestyle changes to avoid and monitor development of the disease. Physicians can leverage a patient’s genetic information to select the optimal treatment strategy.
Blood, urine, tissue, serum, hair, saliva and other bodily fluids and samples are routinely tested for a multitude of conditions, diseases, drugs, biomarkers and other entities using multiple methodologies including ELISA, Fluorescence Polarization Immunoassay [FPIA], homogeneous immunoassays, mass spectrometry and many others.
Oasis Diagnostics® provides proprietary tools to aid laboratory scientists including its Versi•SAL® device for standardized whole saliva collection, UltraSal-2™ for large volume oral specimen collection and Super•SAL™ saliva collection device for universal saliva collection purposes.
With early diagnosis being the key to disease prevention efforts on a global basis and Oasis Diagnostics® as a partner we direct our research efforts to the development of rapid, point-of-care, laboratory based and molecular diagnostic products, which fit into a Corporate objective of improving the quality of healthcare for our global customers.
With defined emphasis on saliva diagnostics, salivary tools and oral-based applications, we are always open to discussing new business opportunities including licensing, distribution and partnering with potential collaborative partners.